Fast-Tracking Biotherapeutic Innovation in Europe with Transient Mammalian Expression
Fremont, CA: The rising demand for next-generation biotherapeutics is reshaping Europe’s biopharmaceutical ecosystem. At the forefront of early drug discovery, transient protein expression in mammalian cells has become a critical enabler of this progress. By rapidly converting genetic insights into functional proteins, this approach serves as a vital link between gene identification and the advancement of clinical-grade biologics, supporting the accelerated timelines required for preclinical research and candidate evaluation.
The Speed of Transient Expression
Transient expression systems are defined by their rapidity and flexibility. Unlike stable cell line generation, which requires weeks or months to integrate the gene of interest into the host cell genome, transient expression allows for the introduction of genetic material for a limited duration. The resulting recombinant protein is then rapidly produced and harvested, typically within days to a couple of weeks post-transfection. This speed is invaluable for high-throughput screening, where researchers need to quickly assess the expression levels, folding, and function of numerous protein candidates, such as therapeutic antibodies or recombinant antigens, to identify the most promising molecules.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The continued prominence of mammalian cell lines, such as HEK293 (Human Embryonic Kidney) and CHO (Chinese Hamster Ovary) derivatives, as the hosts for transient expression in Europe stems from their ability to perform complex post-translational modifications (PTMs). These modifications, including correct protein folding, disulfide bond formation, and, critically, glycosylation, are essential for the biological activity, stability, and immunogenicity of biotherapeutics. They ensure that the transiently expressed material closely resembles the final therapeutic product manufactured in stable cell lines. This early-stage relevance is paramount for reliable preclinical data.
Technological Evolution in Europe
Recent technological advancements have significantly enhanced the capabilities of transient expression platforms across Europe. Optimised expression systems now routinely achieve gram-per-litre yields, a remarkable increase from earlier capabilities. These improvements are multifaceted, encompassing the development of highly efficient transfection reagents, specialised serum-free, high-density cell culture media, and engineered host cell lines with superior growth characteristics and protein productivity.
The implementation of scalable suspension culture systems and advanced bioreactors has transitioned the process, enabling the production of milligram to gram quantities necessary for in vivo animal studies and early toxicology testing. The ability to smoothly scale up transient processes provides essential material fast, dramatically reducing the time-to-clinic for novel biotherapeutic candidates in the European pharmaceutical research and development pipeline. This integration of process optimisation with high-performance components secures the transient expression's essential role in the efficient discovery and development of next-generation biologics.
Transient protein expression in mammalian cells has cemented its position as an indispensable cornerstone of biotherapeutic discovery across Europe. The inherent speed and flexibility of this methodology, combined with continuous advancements in host cell lines and expression systems, directly address the pharmaceutical industry's need for rapid candidate screening and material generation. By providing high-quality, biologically relevant proteins in a matter of weeks—material that accurately mimics the final therapeutic product—transient expression accelerates the critical transition from gene concept to preclinical validation. As European biopharma continues its pursuit of novel and complex biologics, the power of this technology will remain central to compressing timelines and efficiently driving the next wave of therapeutic innovations.
More in News
Life science proficiency testing service providers have emerged as indispensable components in the quality control process for all research laboratories, diagnostic laboratories, pharmaceutical companies, biotech firms, and regulatory bodies. Given that scientific activity has been increasing in complexity, there is a need for laboratories to have reliable mechanisms for measuring their analytical performance and validating test accuracy. The process of proficiency testing involves conducting independent evaluations through comparison to standards and other laboratories.
Organizations that make use of proficiency testing services are showing their dedication towards quality management, constant improvement, and dependable scientific results, leading to increased confidence among stakeholders, partners, regulatory bodies, and clients in the highly competitive life science industry.
Strengthening Laboratory Quality through Independent Performance Evaluation
The first and foremost purpose of life science proficiency testing is to determine the performance of a laboratory based on standard test materials. This process enables laboratories to assess the analytical performance against the expected values while determining the areas that need improvement. Proficiency testing is not just limited to compliance but is an effective management tool that aids decision-making within laboratories.
Consistent participation allows the laboratory to evaluate its test accuracy and identify trends before they affect the lab’s operations. Regular evaluation is useful in confirming the efficiency of testing techniques, instrument performance, personnel competence, and internal quality controls. Through the early identification of performance trends, necessary corrective measures can be taken to ensure the reliability of the lab operations.
A third major benefit relates to the ability to meet accreditation requirements. Many laboratories work under tightly controlled conditions, where it is important to prove technical proficiency. Proficiency testing helps provide proof that the analysis process produces reliable results. This information is useful not only for external evaluations but also for building trust in clients and collaborators.
As lab technology advances, there is an expansion of the proficiency testing program to cater to the development of new test methods, testing systems, and scientific fields. Providers of service keep on developing testing methods that correspond to the advancement of laboratories so that those participating can be able to assess their performances with methods that correspond to the current technological advancements.
Supporting Operational Efficiency and Continuous Improvement
Proficiency testing in the life sciences not only helps with quality assurance but is a tool for improving efficiency through the practice of monitoring performance and refining processes. Those laboratories that analyze their proficiency test results have the opportunity to assess the effectiveness of their procedures, their resource usage, and how consistent the process is.
Professional development of employees is also enhanced through proficiency testing participation in a formalized manner. The professionals in laboratories get objective information on their performance in terms of their technical skills, which in turn helps in training programs aimed at enhancing analytical skills. This promotes continuous learning among employees as well as standardization of the tests in laboratories.
Information about equipment maintenance, method validation and other operational processes is also derived from data gathered via proficiency testing. The trend of performance can be used to identify areas where improvements in the calibration process, quality information, and standard operating procedures can be made. Such initiatives will help to minimize variations and improve performance.
Communication by the testing agencies and the laboratories that participate is even more useful for the success of the program. The information and training that laboratories can get from performance reports, technical assistance, and educational materials will assist in understanding the results of the evaluation and making improvements.
Advancements in technology, in terms of the use of digitized techniques, have made proficiency testing easier and more convenient. Digitized reporting systems, data analysis software, and information management systems have helped make the process easy for participants and minimize the amount of work for administrators. Technology has enabled laboratories to concentrate more on scientific work.
Building Long-Term Business Value through Reliable Scientific Performance
High-quality laboratory work adds tangible business value in the life sciences industry through such activities as product development, submission to regulatory authorities, research partnerships, and business decision-making. Those businesses that consistently provide analytically accurate data enhance their professional standing, as well as build confidence in their customer base and regulatory partners. Proficiency testing is thus more than a quality process; it is a strategic business move.
As collaboration in science on a global scale increases, there is a greater tendency for laboratories to engage in multicenter studies, international research projects, and also regulatory activities involving cross-border collaboration. Proficiency testing through standardization enables the creation of a level of consistency in analytical results within the laboratory, thus promoting collaborative science efforts.
Future trends in the domain of life science proficiency testing services are expected to center around increased automation, data analysis capabilities, a wider range of testing options, and increased digitalization. Service providers that continue to innovate while preserving their scientific integrity will continue to be an asset to laboratories in search of reliable quality assurance solutions. Through the application of technical knowledge, continuous improvement, and excellent client service, the proficiency testing services help to enhance laboratory performance and efficiency as well as scientific integrity. ...Read more
Clinical laboratories have always played an essential role in healthcare, but their influence now reaches far beyond test results. Every diagnosis, treatment plan and disease monitoring strategy depends on reliable laboratory data. What was once viewed primarily as a support function has become a critical contributor to clinical decision-making across the healthcare system.
That shift is changing how healthcare organizations invest in laboratory capabilities. Hospitals, health systems and independent laboratories face growing demand for faster turnaround times, greater testing capacity and increasingly complex diagnostic services. Rising rates of chronic disease, an aging population and advances in precision medicine continue to increase the volume and sophistication of laboratory testing.
The market reflects that momentum. Industry estimates place the global clinical laboratory services market at well over USD 250 billion, with steady growth expected throughout the coming decade. Demand continues to rise as healthcare providers rely more heavily on laboratory data to guide diagnosis, monitor treatment and improve patient outcomes.
“Precision medicine is creating new opportunities, but it also requires laboratories to develop specialized expertise and adopt more sophisticated technologies.”
North America remains one of the largest markets for clinical laboratory services, supported by advanced healthcare infrastructure, strong investment in diagnostics and continued innovation across laboratory technologies.
Technology Is Reshaping Laboratory Workflows
The modern clinical laboratory looks very different from the one that existed a decade ago. Automation has become a central part of laboratory operations. Routine processes that once required significant manual effort are increasingly handled by automated analyzers and robotic systems, allowing laboratory professionals to process higher test volumes while improving consistency.
Digital platforms are also changing how laboratories manage information. Laboratory information systems connect instruments, patient records and reporting workflows, giving clinicians faster access to results and reducing the risk of transcription errors.
Molecular diagnostics continue to expand the laboratory’s role. Advances in genetic testing, biomarker analysis and next-generation sequencing are helping clinicians identify diseases earlier and select therapies that are better matched to individual patients. Precision medicine is creating new opportunities, but it also requires laboratories to develop specialized expertise and adopt more sophisticated technologies.
Demand Continues to Grow Across Healthcare
Several long-term trends continue to shape the clinical laboratory market. Chronic diseases such as diabetes, cardiovascular disease and cancer require regular monitoring, increasing the demand for laboratory testing throughout a patient’s care journey.
Preventive healthcare is also becoming more common. Earlier diagnosis and routine screening programs are expanding testing volumes across primary care, specialty clinics and community health settings.
Public health preparedness remains another important priority. Lessons learned during recent global health emergencies reinforced the need for laboratory networks that can rapidly scale testing capacity while maintaining quality and accuracy.
Patients have become more engaged in their healthcare decisions as well. Many now expect quicker access to test results, greater transparency and more convenient testing options, encouraging laboratories to improve both efficiency and the patient experience.
What Healthcare Organizations Expect From Laboratory Partners.
Choosing a clinical laboratory is no longer based solely on testing capability. Healthcare organizations evaluate laboratories across a broader range of factors, including quality systems, regulatory compliance, turnaround times and the ability to support increasingly complex diagnostic requirements.
Integration has become equally important. Laboratory systems are expected to connect smoothly with electronic health records and other healthcare platforms, allowing clinicians to access results quickly and incorporate laboratory data into broader care decisions.
Scalability also plays an important role. Laboratories must be able to accommodate fluctuations in testing volumes without compromising quality or turnaround times. Workforce challenges continue to affect the sector. Many laboratories face shortages of experienced professionals while managing growing testing demand. Automation and digital technologies help address some of these pressures, yet skilled laboratory scientists remain essential for complex analysis, quality assurance and clinical interpretation.
Standardization presents another ongoing challenge. Large health systems often operate multiple laboratories with different equipment, workflows and reporting practices. Greater consistency across laboratory networks can improve efficiency while supporting more reliable clinical outcomes.
A Broader Role in the Future of Healthcare
Clinical laboratories are becoming increasingly central to modern healthcare. Advances in diagnostics, precision medicine and digital health will continue to expand the laboratory’s contribution to patient care. At the same time, healthcare organizations will expect laboratories to deliver faster results, greater accuracy and stronger data integration while maintaining rigorous quality standards.
Future investment is likely to focus on technologies that improve efficiency without sacrificing clinical confidence. Automation, molecular diagnostics and connected laboratory systems will continue to shape how testing services evolve over the coming years.
Clinical laboratories are no longer viewed simply as places where samples are analyzed. They have become trusted partners in diagnosis, disease management and clinical decision-making, helping healthcare providers deliver more informed care in an increasingly complex healthcare environment. ...Read more
Stem cell treatment centers are becoming more important in regions where patients need complex transplant services but must travel far from home for care. While public attention often focuses on regenerative medicine clinics, established stem cell treatment is most mature in areas such as blood cancers and serious blood disorders, where transplant programs require specialized hospital infrastructure.
A recent report from Australia described a campaign to establish a donor stem cell transplant service at Townsville University Hospital. The initiative aims to reduce the need for patients in North Queensland to travel to Brisbane for Total Body Irradiation before some stem cell transplants. This process can force patients and full-time carers to live away from home for months.
Where stem cell treatment is available can have a significant impact on the patient experience. Treatment often involves much more than a single clinical procedure, including pre-treatment conditioning, donor coordination, infection monitoring and an extended period of recovery. When these services are concentrated in major cities, patients and their families may have to travel long distances, take extended time away from work or home and manage the financial and personal strain that comes with receiving care far from their local community.
Treatment centers that expand access must still maintain high standards. A transplant program needs trained clinicians, laboratory support, inpatient capacity and emergency response systems. The complexity makes it different from office-based regenerative medicine offerings that may be marketed directly to consumers.
Health systems are therefore looking at hub-and-spoke models. A major center may manage advanced procedures, while regional providers support testing, follow-up care and patient education.
Expanding stem cell treatment services depends on people as much as infrastructure. A successful program requires experienced hematologists, transplant nurses, pharmacists and laboratory teams working together throughout the patient's care journey. Investing in equipment alone is not enough. Centers also need a coordinated model of care that can support patients before treatment, during therapy and throughout recovery.
For patients considering stem cell treatment, it should be clear whether a service is part of an established hospital program or an unapproved commercial offering. That distinction has become increasingly important as stem cell therapies attract wider attention. The FDA continues to advise consumers to avoid unapproved products made from human cells or tissues that are marketed online with broad treatment claims.
Stem cell treatment providers are increasingly following different paths. Hospital-based programs continue to build around approved therapies, multidisciplinary care and the clinical infrastructure needed to manage complex patients. At the same time, commercial clinics offering unapproved interventions are coming under closer regulatory and scientific scrutiny. As more treatment options emerge, centers that expand access without compromising clinical standards are likely to earn greater confidence from patients, physicians and regulators. ...Read more
Shortages in generic and biopharmaceutical medicines rarely begin as a single missed shipment. They build earlier, in product selection, dossier timing, plant readiness, inspection discipline and the handoffs between development teams and commercial supply. Healthcare systems and pharmaceutical partners face more than price exposure. A low-cost product that reaches the market late, produces incomplete regulatory documentation, strains sterile capacity or fails to sustain supply can create treatment gaps that procurement teams cannot correct once contracts are awarded.
The buying decision has moved beyond simple generic substitution. Sterile injectables and biosimilars carry tighter technical demands, while European launch planning adds country-by-country complexity in access policy, reimbursement, tender timing and route-to-market execution. Companies need development partners who can meet quality requirements while managing the economic pressures that drive the adoption of generics and biosimilars. This balance is difficult when discovery, clinical work, manufacturing and market entry are organised into disconnected supplier arrangements. Each handoff adds room for delay, unclear accountability, cost drift and late discovery of supply constraints.
Capacity alone does not settle the question. Value comes from operations that are audit-ready, disciplined in production planning and transparent throughout the supply chain. Customers benefit when manufacturing partners work within a shared planning rhythm. Procurement and commercial teams identify issues earlier when both sides align on demand, filing schedules, quality assessment and supplier risk. Close alignment prevents cost pressure from eroding quality standards or pushing corrective work past the launch calendar.
Portfolio strategy carries equal weight. A partner built solely around commodity generics may struggle when buyers need sterile dosage forms, peptides, complex injectables and biosimilars on a single development path. Breadth becomes a liability without disciplined product choice and clear market sequencing. Selective expansion is the stronger path, backed by investment in development capacity, credible regulatory preparation, experienced European staff and a realistic view of market entry. Europe is not one launch environment. It is a cluster of pricing rules, health system practices, tender calendars and local access requirements. The real question is whether a partner can connect scientific development, compliance preparation, manufacturing scale and commercial timing without leaving the buyer to manage every gap.
Evumed Limited’s model centres on pharmaceutical development and commercialisation as a whole. Its European headquarters in Cork, Ireland, covers regulatory affairs, quality, supply chain management and commercial support. Its strategic partnership with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd and Evumed Singapore, adds depth to its manufacturing and research and development. Its portfolio spans generic medicines, sterile injectables, peptides and biosimilars, backed by FDA-inspected facilities, expanding sterile production capacity and continued biosimilar investment. Development, manufacturing and market access work as a connected system, built to sustain supply and shorten the path to European market entry. ...Read more
